BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36094689)

  • 1. Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and Outcomes.
    Baratti D; Kusamura S; Guaglio M; Milione M; Pietrantonio F; Cavalleri T; Morano F; Deraco M
    Ann Surg Oncol; 2023 Jan; 30(1):404-414. PubMed ID: 36094689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes.
    Baratti D; Milito P; Kusamura S; Martin Roman L; Guaglio M; Deraco M
    Eur J Surg Oncol; 2022 Jul; 48(7):1590-1597. PubMed ID: 35090796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei.
    Delhorme JB; Honoré C; Benhaim L; Dumont F; Dartigues P; Dromain C; Ducreux M; Elias D; Goéré D
    Eur J Surg Oncol; 2017 Jan; 43(1):159-167. PubMed ID: 27646440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
    Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
    Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
    Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
    Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
    Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Gelli M; Huguenin JFL; de Baere T; Benhaim L; Mariani A; Boige V; Malka D; Sourouille I; Ducreux M; Elias D; Goéré D
    Eur J Cancer; 2018 Sep; 100():94-103. PubMed ID: 30014885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
    van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
    BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
    Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
    J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.